Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 74 entries
Sorted by: Best Match Show Resources per page
Isolation and characterization of muscle fatigue substance with anti-tumor activities.

Journal of Cancer

Munoz RM, Han H, Tegeler T, Petritis K, Von Hoff DD, Hoffman SA.
PMID: 23678371
J Cancer. 2013 May 09;4(4):343-9. doi: 10.7150/jca.5418. Print 2013.

Research during the 1950's indicated that exercise played a role in the reduction of tumor growth. In the 1960's our studies confirmed that tumor-bearing rats, exercised to fatigue, demonstrated tumor inhibition. Our further studies isolated an extract (Fatigue Substance,...

Cite
Munoz RM, Han H, Tegeler T, et al. Isolation and characterization of muscle fatigue substance with anti-tumor activities. J Cancer. 2013;4(4):343-9doi: 10.7150/jca.5418.
Munoz, R. M., Han, H., Tegeler, T., Petritis, K., Von Hoff, D. D., & Hoffman, S. A. (2013). Isolation and characterization of muscle fatigue substance with anti-tumor activities. Journal of Cancer, 4(4), 343-9. https://doi.org/10.7150/jca.5418
Munoz, Ruben M, et al. "Isolation and characterization of muscle fatigue substance with anti-tumor activities." Journal of Cancer vol. 4,4 (2013): 343-9. doi: https://doi.org/10.7150/jca.5418
Munoz RM, Han H, Tegeler T, Petritis K, Von Hoff DD, Hoffman SA. Isolation and characterization of muscle fatigue substance with anti-tumor activities. J Cancer. 2013 May 09;4(4):343-9. doi: 10.7150/jca.5418. Print 2013. PMID: 23678371; PMCID: PMC3654491.
Copy Download .nbib Format: NLM
RESPONSE: re: measure once or twice-does It really matter?.

Journal of the National Cancer Institute

Hilsenbeck SG, Von Hoff DD.
PMID: 10528033
J Natl Cancer Inst. 1999 Oct 20;91(20):1780A-1781. doi: 10.1093/jnci/91.20.1780a.

No abstract available.

Cite
Hilsenbeck SG, Von Hoff DD. RESPONSE: re: measure once or twice-does It really matter?. J Natl Cancer Inst. 1999;91(20):1780A-1781doi: 10.1093/jnci/91.20.1780a.
Hilsenbeck, S. G., & Von Hoff DD. (1999). RESPONSE: re: measure once or twice-does It really matter?. Journal of the National Cancer Institute, 91(20), 1780A-1781. https://doi.org/10.1093/jnci/91.20.1780a
Hilsenbeck, and Von Hoff DD. "RESPONSE: re: measure once or twice-does It really matter?." Journal of the National Cancer Institute vol. 91,20 (1999): 1780A-1781. doi: https://doi.org/10.1093/jnci/91.20.1780a
Hilsenbeck SG, Von Hoff DD. RESPONSE: re: measure once or twice-does It really matter?. J Natl Cancer Inst. 1999 Oct 20;91(20):1780A-1781. doi: 10.1093/jnci/91.20.1780a. PMID: 10528033.
Copy Download .nbib Format: NLM
Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis.

Apoptosis : an international journal on programmed cell death

Petit T, Davidson K, Izbicka E, Von Hoff DD.
PMID: 14634278
Apoptosis. 1999 Jun;4(3):163-7. doi: 10.1023/a:1009606421419.

Hydroxyurea (HU) increases extrachromosomal DNA elimination in tumor cell lines. The c-myc oncogene is one of the many relevant amplified genes contained within the extrachromosomal DNA compartment. Spontaneous loss of amplified copies of c-myc induces terminal differentiation and apoptosis...

Cite
Petit T, Davidson K, Izbicka E, et al. Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis. Apoptosis. 1999;4(3):163-7doi: 10.1023/a:1009606421419.
Petit, T., Davidson, K., Izbicka, E., & Von Hoff, D. D. (1999). Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis. Apoptosis : an international journal on programmed cell death, 4(3), 163-7. https://doi.org/10.1023/a:1009606421419
Petit, T, et al. "Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis." Apoptosis : an international journal on programmed cell death vol. 4,3 (1999): 163-7. doi: https://doi.org/10.1023/a:1009606421419
Petit T, Davidson K, Izbicka E, Von Hoff DD. Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis. Apoptosis. 1999 Jun;4(3):163-7. doi: 10.1023/a:1009606421419. PMID: 14634278.
Copy Download .nbib Format: NLM
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma.

Genome medicine

Evers L, Perez-Mancera PA, Lenkiewicz E, Tang N, Aust D, Knösel T, Rümmele P, Holley T, Kassner M, Aziz M, Ramanathan RK, Von Hoff DD, Yin H, Pilarsky C, Barrett MT.
PMID: 24484537
Genome Med. 2014 Jan 31;6(1):9. doi: 10.1186/gm526. eCollection 2014.

BACKGROUND: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer characterized by complex aberrant genomes. A fundamental goal of current studies is to identify those somatic events arising in the variable landscape of PDA genomes that can be exploited...

Cite
Evers L, Perez-Mancera PA, Lenkiewicz E, et al. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med. 2014;6(1):9doi: 10.1186/gm526.
Evers, L., Perez-Mancera, P. A., Lenkiewicz, E., Tang, N., Aust, D., Knösel, T., Rümmele, P., Holley, T., Kassner, M., Aziz, M., Ramanathan, R. K., Von Hoff, D. D., Yin, H., Pilarsky, C., & Barrett, M. T. (2014). STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome medicine, 6(1), 9. https://doi.org/10.1186/gm526
Evers, Lisa, et al. "STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma." Genome medicine vol. 6,1 (2014): 9. doi: https://doi.org/10.1186/gm526
Evers L, Perez-Mancera PA, Lenkiewicz E, Tang N, Aust D, Knösel T, Rümmele P, Holley T, Kassner M, Aziz M, Ramanathan RK, Von Hoff DD, Yin H, Pilarsky C, Barrett MT. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med. 2014 Jan 31;6(1):9. doi: 10.1186/gm526. eCollection 2014. PMID: 24484537; PMCID: PMC3971348.
Copy Download .nbib Format: NLM
Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability.

Genome medicine

Demeure MJ, Craig DW, Sinari S, Moses TM, Christoforides A, Dinh J, Izatt T, Aldrich J, Decker A, Baker A, Cherni I, Watanabe A, Koep L, Lake D, Hostetter G, Trent JM, Von Hoff DD, Carpten JD.
PMID: 22762308
Genome Med. 2012 Jul 04;4(7):56. doi: 10.1186/gm357. eCollection 2012.

BACKGROUND: Recent advances in the treatment of cancer have focused on targeting genomic aberrations with selective therapeutic agents. In rare tumors, where large-scale clinical trials are daunting, this targeted genomic approach offers a new perspective and hope for improved...

Cite
Demeure MJ, Craig DW, Sinari S, et al. Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome Med. 2012;4(7):56doi: 10.1186/gm357.
Demeure, M. J., Craig, D. W., Sinari, S., Moses, T. M., Christoforides, A., Dinh, J., Izatt, T., Aldrich, J., Decker, A., Baker, A., Cherni, I., Watanabe, A., Koep, L., Lake, D., Hostetter, G., Trent, J. M., Von Hoff, D. D., & Carpten, J. D. (2012). Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome medicine, 4(7), 56. https://doi.org/10.1186/gm357
Demeure, Michael J, et al. "Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability." Genome medicine vol. 4,7 (2012): 56. doi: https://doi.org/10.1186/gm357
Demeure MJ, Craig DW, Sinari S, Moses TM, Christoforides A, Dinh J, Izatt T, Aldrich J, Decker A, Baker A, Cherni I, Watanabe A, Koep L, Lake D, Hostetter G, Trent JM, Von Hoff DD, Carpten JD. Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome Med. 2012 Jul 04;4(7):56. doi: 10.1186/gm357. eCollection 2012. PMID: 22762308; PMCID: PMC3580412.
Copy Download .nbib Format: NLM
Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial.

Neuro-oncology practice

Câmara-Costa H, Bull KS, Kennedy C, Wiener A, Calaminus G, Resch A, Kieffer V, Lalande C, Poggi G, von Hoff K, Grill J, Doz F, Rutkowski S, Massimino M, Kortmann RD, Lannering B, Dellatolas G, Chevignard M.
PMID: 31385949
Neurooncol Pract. 2017 Sep;4(3):161-170. doi: 10.1093/nop/npw028. Epub 2017 Feb 10.

BACKGROUND: The relationship between direct assessments of cognitive performance and questionnaires assessing quality of survival (QoS) is reported to be weak-to-nonexistent. Conversely, the associations between questionnaires evaluating distinct domains of QoS tend to be strong. This pattern remains understudied.METHODS:...

Cite
Câmara-Costa H, Bull KS, Kennedy C, et al. Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neurooncol Pract. 2017;4(3):161-170doi: 10.1093/nop/npw028.
Câmara-Costa, H., Bull, K. S., Kennedy, C., Wiener, A., Calaminus, G., Resch, A., Kieffer, V., Lalande, C., Poggi, G., von Hoff, K., Grill, J., Doz, F., Rutkowski, S., Massimino, M., Kortmann, R. D., Lannering, B., Dellatolas, G., Chevignard, M. (2017). Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neuro-oncology practice, 4(3), 161-170. https://doi.org/10.1093/nop/npw028
Câmara-Costa, Hugo, et al. "Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial." Neuro-oncology practice vol. 4,3 (2017): 161-170. doi: https://doi.org/10.1093/nop/npw028
Câmara-Costa H, Bull KS, Kennedy C, Wiener A, Calaminus G, Resch A, Kieffer V, Lalande C, Poggi G, von Hoff K, Grill J, Doz F, Rutkowski S, Massimino M, Kortmann RD, Lannering B, Dellatolas G, Chevignard M. Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neurooncol Pract. 2017 Sep;4(3):161-170. doi: 10.1093/nop/npw028. Epub 2017 Feb 10. PMID: 31385949; PMCID: PMC6655414.
Copy Download .nbib Format: NLM
Performance status dynamics during treatment with .

Cancer management and research

Chiorean EG, Von Hoff D, Wan Y, Margunato-Debay S, Botteman M, Goldstein D.
PMID: 29910636
Cancer Manag Res. 2018 May 31;10:1389-1396. doi: 10.2147/CMAR.S163475. eCollection 2018.

OBJECTIVES: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient's well-being during treatment with PARTICIPANTS AND METHODS: Descriptive analyses were performed for KPS at three time points (3 and 6 months after randomization and...

Cite
Chiorean EG, Von Hoff D, Wan Y, et al. Performance status dynamics during treatment with . Cancer Manag Res. 2018;10:1389-1396doi: 10.2147/CMAR.S163475.
Chiorean, E. G., Von Hoff, D., Wan, Y., Margunato-Debay, S., Botteman, M., & Goldstein, D. (2018). Performance status dynamics during treatment with . Cancer management and research, 101389-1396. https://doi.org/10.2147/CMAR.S163475
Chiorean, E Gabriela, et al. "Performance status dynamics during treatment with ." Cancer management and research vol. 10 (2018): 1389-1396. doi: https://doi.org/10.2147/CMAR.S163475
Chiorean EG, Von Hoff D, Wan Y, Margunato-Debay S, Botteman M, Goldstein D. Performance status dynamics during treatment with . Cancer Manag Res. 2018 May 31;10:1389-1396. doi: 10.2147/CMAR.S163475. eCollection 2018. PMID: 29910636; PMCID: PMC5987855.
Copy Download .nbib Format: NLM
Author Correction: The landscape of genomic alterations across childhood cancers.

Nature

Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM.
PMID: 29875405
Nature. 2018 Jul;559(7714):E10. doi: 10.1038/s41586-018-0167-2.

In this Article, author Benedikt Brors was erroneously associated with affiliation number '8' (Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee, USA); the author's two other affiliations (affiliations '3' and '7', both at the German Cancer...

Cite
Gröbner SN, Worst BC, Weischenfeldt J, et al. Author Correction: The landscape of genomic alterations across childhood cancers. Nature. 2018;559(7714):E10doi: 10.1038/s41586-018-0167-2.
Gröbner, S. N., Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., Segura-Wang, M., Brabetz, S., Bender, S., Hutter, B., Sturm, D., Pfaff, E., Hübschmann, D., Zipprich, G., Heinold, M., Eils, J., Lawerenz, C., Erkek, S., Lambo, S., Waszak, S., Blattmann, C., Borkhardt, A., Kuhlen, M., Eggert, A., Fulda, S., Gessler, M., Wegert, J., Kappler, R., Baumhoer, D., Burdach, S., Kirschner-Schwabe, R., Kontny, U., Kulozik, A. E., Lohmann, D., Hettmer, S., Eckert, C., Bielack, S., Nathrath, M., Niemeyer, C., Richter, G. H., Schulte, J., Siebert, R., Westermann, F., Molenaar, J. J., Vassal, G., Witt, H., Burkhardt, B., Kratz, C. P., Witt, O., van Tilburg, C. M., Kramm, C. M., Fleischhack, G., Dirksen, U., Rutkowski, S., Frühwald, M., von Hoff, K., Wolf, S., Klingebiel, T., Koscielniak, E., Landgraf, P., Koster, J., Resnick, A. C., Zhang, J., Liu, Y., Zhou, X., Waanders, A. J., Zwijnenburg, D. A., Raman, P., Brors, B., Weber, U. D., Northcott, P. A., Pajtler, K. W., Kool, M., Piro, R. M., Korbel, J. O., Schlesner, M., Eils, R., Jones, D. T. W., Lichter, P., Chavez, L., Zapatka, M., Pfister, S. M. (2018). Author Correction: The landscape of genomic alterations across childhood cancers. Nature, 559(7714), E10. https://doi.org/10.1038/s41586-018-0167-2
Gröbner, Susanne N, et al. "Author Correction: The landscape of genomic alterations across childhood cancers." Nature vol. 559,7714 (2018): E10. doi: https://doi.org/10.1038/s41586-018-0167-2
Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM. Author Correction: The landscape of genomic alterations across childhood cancers. Nature. 2018 Jul;559(7714):E10. doi: 10.1038/s41586-018-0167-2. PMID: 29875405.
Copy Download .nbib Format: NLM
Altered expression of costimulatory molecules in dementias.

European archives of psychiatry and clinical neuroscience

Busse S, von Hoff F, Michler E, Hartig R, Bogerts B, Busse M.
PMID: 34427746
Eur Arch Psychiatry Clin Neurosci. 2021 Aug 24; doi: 10.1007/s00406-021-01297-1. Epub 2021 Aug 24.

Although the expression of co-stimulatory molecules plays an important role in the immune system, only little is known about their regulation in dementias. Therefore, we determined the expression of CD28, ICOS (CD278) and CTLA-4 (CD152) by CD4 + and...

Cite
Busse S, von Hoff F, Michler E, et al. Altered expression of costimulatory molecules in dementias. Eur Arch Psychiatry Clin Neurosci. 2021;doi: 10.1007/s00406-021-01297-1.
Busse, S., von Hoff, F., Michler, E., Hartig, R., Bogerts, B., & Busse, M. (2021). Altered expression of costimulatory molecules in dementias. European archives of psychiatry and clinical neuroscience, . https://doi.org/10.1007/s00406-021-01297-1
Busse, Stefan, et al. "Altered expression of costimulatory molecules in dementias." European archives of psychiatry and clinical neuroscience vol. (2021). doi: https://doi.org/10.1007/s00406-021-01297-1
Busse S, von Hoff F, Michler E, Hartig R, Bogerts B, Busse M. Altered expression of costimulatory molecules in dementias. Eur Arch Psychiatry Clin Neurosci. 2021 Aug 24; doi: 10.1007/s00406-021-01297-1. Epub 2021 Aug 24. PMID: 34427746.
Copy Download .nbib Format: NLM
Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.

Seminars in cancer biology

Sharma GG, Okada Y, Von Hoff D, Goel A.
PMID: 33049362
Semin Cancer Biol. 2021 Oct;75:153-168. doi: 10.1016/j.semcancer.2020.10.001. Epub 2020 Oct 10.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, which is usually diagnosed at an advanced stage. The late disease diagnosis, the limited availability of effective therapeutic interventions and lack of robust diagnostic biomarkers, are some of...

Cite
Sharma GG, Okada Y, Von Hoff D, et al. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol. 2020;75:153-168doi: 10.1016/j.semcancer.2020.10.001.
Sharma, G. G., Okada, Y., Von Hoff, D., & Goel, A. (2021). Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Seminars in cancer biology, 75153-168. https://doi.org/10.1016/j.semcancer.2020.10.001
Sharma, Geeta G, et al. "Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma." Seminars in cancer biology vol. 75 (2021): 153-168. doi: https://doi.org/10.1016/j.semcancer.2020.10.001
Sharma GG, Okada Y, Von Hoff D, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol. 2021 Oct;75:153-168. doi: 10.1016/j.semcancer.2020.10.001. Epub 2020 Oct 10. PMID: 33049362; PMCID: PMC8035348.
Copy Download .nbib Format: NLM
CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.

Cancer gene therapy

Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim SI, Warner SG, Yuan YC, Liu Z, Han H, Von Hoff D, Fong Y, Woo Y.
PMID: 34108669
Cancer Gene Ther. 2021 Jun 09; doi: 10.1038/s41417-021-00350-4. Epub 2021 Jun 09.

Immunotherapeutic strategies that combine oncolytic virus (OV) and immune checkpoint inhibitors have the potential to overcome treatment resistance in pancreatic ductal adenocarcinoma (PDAC), one of the least immunogenic solid tumors. Oncolytic viral chimera, CF33-hNIS-antiPDL1 genetically modified to express anti-human...

Cite
Zhang Z, Yang A, Chaurasiya S, et al. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2021;doi: 10.1038/s41417-021-00350-4.
Zhang, Z., Yang, A., Chaurasiya, S., Park, A. K., Lu, J., Kim, S. I., Warner, S. G., Yuan, Y. C., Liu, Z., Han, H., Von Hoff, D., Fong, Y., & Woo, Y. (2021). CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer gene therapy, . https://doi.org/10.1038/s41417-021-00350-4
Zhang, Zhifang, et al. "CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy." Cancer gene therapy vol. (2021). doi: https://doi.org/10.1038/s41417-021-00350-4
Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim SI, Warner SG, Yuan YC, Liu Z, Han H, Von Hoff D, Fong Y, Woo Y. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2021 Jun 09; doi: 10.1038/s41417-021-00350-4. Epub 2021 Jun 09. PMID: 34108669.
Copy Download .nbib Format: NLM
CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.

Cancer gene therapy

Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim SI, Warner SG, Yuan YC, Liu Z, Han H, Von Hoff D, Fong Y, Woo Y.
PMID: 34108669
Cancer Gene Ther. 2021 Jun 09; doi: 10.1038/s41417-021-00350-4. Epub 2021 Jun 09.

Immunotherapeutic strategies that combine oncolytic virus (OV) and immune checkpoint inhibitors have the potential to overcome treatment resistance in pancreatic ductal adenocarcinoma (PDAC), one of the least immunogenic solid tumors. Oncolytic viral chimera, CF33-hNIS-antiPDL1 genetically modified to express anti-human...

Cite
Zhang Z, Yang A, Chaurasiya S, et al. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2021;doi: 10.1038/s41417-021-00350-4.
Zhang, Z., Yang, A., Chaurasiya, S., Park, A. K., Lu, J., Kim, S. I., Warner, S. G., Yuan, Y. C., Liu, Z., Han, H., Von Hoff, D., Fong, Y., & Woo, Y. (2021). CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer gene therapy, . https://doi.org/10.1038/s41417-021-00350-4
Zhang, Zhifang, et al. "CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy." Cancer gene therapy vol. (2021). doi: https://doi.org/10.1038/s41417-021-00350-4
Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim SI, Warner SG, Yuan YC, Liu Z, Han H, Von Hoff D, Fong Y, Woo Y. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2021 Jun 09; doi: 10.1038/s41417-021-00350-4. Epub 2021 Jun 09. PMID: 34108669.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 74 entries